Tirzepatide
A dual GIP/GLP-1 receptor agonist for weight and glucose management.
Overview
Tirzepatide is a groundbreaking, FDA-approved peptide that simultaneously activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The dual action is credited with its potent effects on weight loss and glycemic control, marketed as Mounjaro and Zepbound.
Dosing
Injection
- Starting dose
- 2.5 mg/wk
- Common dose
- 5–15 mg/wk
- Frequency
- 1× weekly
- Notes
- Titrate in 2.5 mg steps every 4 weeks.
Reported research/reference doses for educational purposes only. Always verify against primary literature and applicable regulations. Not medical advice.
How it works
By co-activating GIP and GLP-1 receptors, tirzepatide enhances insulin secretion, suppresses glucagon, slows gastric emptying, and strongly reduces appetite and food intake. The combined signaling is associated with greater weight reduction than GLP-1 agonism alone.
Common research uses
- Chronic weight management
- Type 2 diabetes glucose control
- Appetite and satiety research
- Metabolic syndrome studies
Considerations
Prescription medication requiring medical oversight. Potential gastrointestinal side effects; thyroid tumor warning in rodents. Prescription use only.